DrugPatentWatch Database Preview
Celgene Corp Company Profile
What is the competitive landscape for CELGENE CORP, and what generic alternatives to CELGENE CORP drugs are available?
CELGENE CORP has two approved drugs.
There are thirteen US patents protecting CELGENE CORP drugs.
There are one hundred and twenty-eight patent family members on CELGENE CORP drugs in thirty-one countries.
Summary for Celgene Corp
| International Patents: | 128 |
| US Patents: | 13 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
| Drug Master File Entries: | 4 |
| Patent Litigation for Celgene Corp: | See patent lawsuits for Celgene Corp |
| PTAB Cases with Celgene Corp as patent owner: | See PTAB cases with Celgene Corp as patent owner |
Drugs and US Patents for Celgene Corp
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Celgene Corp | OTEZLA | apremilast | TABLET;ORAL | 205437-002 | Mar 21, 2014 | RX | Yes | No | 6,020,358 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Celgene Corp | IDHIFA | enasidenib mesylate | TABLET;ORAL | 209606-001 | Aug 1, 2017 | RX | Yes | No | 9,732,062 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Celgene Corp | OTEZLA | apremilast | TABLET;ORAL | 205437-003 | Mar 21, 2014 | RX | Yes | Yes | 8,455,536 | ➤ Sign Up | ➤ Sign Up | ||||
| Celgene Corp | OTEZLA | apremilast | TABLET;ORAL | 205437-001 | Mar 21, 2014 | RX | Yes | No | 8,802,717 | ➤ Sign Up | ➤ Sign Up | ||||
| Celgene Corp | OTEZLA | apremilast | TABLET;ORAL | 205437-002 | Mar 21, 2014 | RX | Yes | No | 8,802,717 | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for CELGENE CORP drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 10 mg, 20 mg and30 mg | ➤ Subscribe | 2018-03-22 |
Non-Orange Book US Patents for Celgene Corp
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,093,283 | Solid forms comprising (+)-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisi- noline-1,3-dione, compositions thereof, and uses thereof | ➤ Sign Up |
| 6,011,050 | Substituted phenethylsulfones and method of reducing TNF.alpha. levels | ➤ Sign Up |
| 8,629,173 | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione, compositions thereof, and uses thereof | ➤ Sign Up |
| 7,358,272 | Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione | ➤ Sign Up |
| 9,433,606 | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione, compositions thereof, and uses thereof | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Celgene Corp Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Hungary | E029682 | ➤ Sign Up |
| Israel | 233503 | ➤ Sign Up |
| Spain | 2421153 | ➤ Sign Up |
| Denmark | 2295055 | ➤ Sign Up |
| South Korea | 20130100219 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.
